Neuroplast spinal cord injury study milestone

The cell-based treatment company Neuroplast, has successfully completed its phase 2 trial based on patient inclusion. The research aimed to analyse the impact of its ‘Neuro-cells’ among individuals with traumatic spinal cord injuries. The trial was conducted in collaboration with the Hospital Nacional de Parapléjicos in Toledo, Spain, and Rigshospitalet in Copenhagen, Denmark.

 
The study involves sixteen patients who sustained such injuries six to ten weeks prior to the trial. The study was a placebo-controlled, randomized, and double-blinded clinical trial. Patient feedback has confirmed excellent tolerability. The data presented in the trial exhibited a great safety record as there were no adverse events related to its use.

The Neuro-Cells technology platform utilizes an individual’s bone marrow to develop a stem cell treatment that helps regulate inflammation and enhances the ability of the central nervous system to regenerate. This personalized therapy is designed to maintain and improve function, mobility, and independence.

Johannes de Munter, chief executive officer at Neuroplast, has said, ‘This milestone takes us one step closer to offering an effective treatment for patients suffering from traumatic spinal cord injury. We are especially glad to see further confirmation of the excellent tolerability and safety of our Neuro-Cells product.